DUBLIN--(BUSINESS WIRE)--The "Coronavirus Vaccine - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
The Global Coronavirus Vaccine market accounted for $18.69 million in 2018 and is expected to reach $900.14 million by 2027 growing at a CAGR of 53.8% during the forecast period.
The increasing prevalence of virus infected people across the world is anticipated to drive the growth of the market. However, factors such as the high costs involved in research and development of therapeutic vaccines and drugs, and time required for each stage of clinical trials are hampering the market growth.
Coronaviruses are a group of viruses that cause diseases or infections in mammals as well as birds. Coronaviruses belong to the Coronaviridae or Torovirinae subfamily. Symptoms caused by these viruses include common cold to serious infections, pneumonia, strict respiratory complications, even kidney failure, and death. These symptoms are common among persons with a weak immune system, individuals with cardiopulmonary disease, infants, and elderly people.
Based on the vaccine type, the DNA-based vaccine segment is going to have a lucrative growth during the forecast period the technological advancements in the field of the pharmaceutical industry have resulted in the development of various effective types of vaccines such as DNA-based nucleic acid vaccines. The use of these vaccines on the human body leads to the development of anti-gen. Thus, the effectiveness of the vaccine against the virus is enhanced significantly.
By geography, Europe is likely to have a huge demand due to diverse coronavirus outbreaks in the current past and the presence of major players in countries in the region. As well, rising investments in R&D activities, along with strong support from the government is driving the growth of the target market in this region.
Some of the key players profiled in the Coronavirus Vaccine Market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart and Vaxil Bio Ltd.
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Key Topics Covered:
1 Executive Summary
3 Market Trend Analysis
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Coronavirus Vaccine Market, By Infection Type
5.6 New Haven CoV
6 Global Coronavirus Vaccine Market, By Vaccine Type
6.2 S-Protein Based Coronavirus Vaccine
6.3 Live Attenuated Coronavirus Vaccine
6.4 Inactivated Coronavirus Vaccine
6.5 mRNA Vaccine
6.6 DNA-Based Vaccine
7 Global Coronavirus Vaccine Market, By Product Type
7.2 Monovalent Vaccine v/s Multivariant Vaccine
8 Global Coronavirus Vaccine Market, By Route of Administration
9 Global Coronavirus Vaccine Market, By Patient Type
10 Global Coronavirus Vaccine Market, By End User
10.4 Research Institutes
11 Global Coronavirus Vaccine Market, By Geography
11.2 North America
11.4 Asia Pacific
11.5 South America
11.6 Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.5 Other Key Strategies
13 Company Profiling
13.1 Inovio Pharmaceuticals, Inc.
13.2 Moderna, Inc.
13.3 Protein Potential, LLC
13.4 Novavax, Inc.
13.5 Synairgen PLC
13.6 AlphaVax, Inc.
13.7 NanoViricides, Inc.
13.8 Zydus Cadila
13.12 Janssen Pharmaceutical Companies
13.13 CanSino Biologics
13.15 Vaxil Bio Ltd
For more information about this report visit https://www.researchandmarkets.com/r/m8r46r